Abstract Number: 806 • 2017 ACR/ARHP Annual Meeting
Epidemiological Study of Giant Cell Arteritis Using a Japanese Administrative Database
Background/Purpose: The giant cell arteritis (GCA) management requires the administration of high-dose glucocorticoid (GC) at the introduction remission and the gradual reduction of the dosage.…Abstract Number: 807 • 2017 ACR/ARHP Annual Meeting
B Cells in Giant Cell Arteritis: a Novel Target for Treatment?
Background/Purpose: Giant cell arteritis (GCA) is the most common type of systemic vasculitis. Currently, two forms of GCA are described: a cranial(C)-GCA (temporal arteritis) and…Abstract Number: 808 • 2017 ACR/ARHP Annual Meeting
Assessing the Possible Link between Varicella Zoster Virus and Giant Cell Arteritis Using Clinical Assessment, Serology and Biopsy Antigen Detection – Interim Results from the Giant Cell Arteritis and PET Scan (GAPS) Cohort
Background/Purpose: Recent studies have suggested that giant cell arteritis (GCA) may be triggered by reactivation of varicella zoster virus (VZV) based on high rates of…Abstract Number: 809 • 2017 ACR/ARHP Annual Meeting
Prevalence and Distribution of Vascular FDG Uptake on Positron Emission Tomography (PET)-CT in Patients Suspected of Having Giant Cell Arteritis – Interim Results from the Giant Cell Arteritis and PET Scan (GAPS) Study
Background/Purpose: Positron emission tomography (PET)-CT scan can assess large vessel vasculitis in giant cell arteritis (GCA). It has a reported sensitivity of 80% for biopsy…Abstract Number: 810 • 2017 ACR/ARHP Annual Meeting
Sensitivity of Temporal Artery Biopsy in Giant Cell Arteritis: Systematic Literature Review and Meta-Analysis of Clinical Data
Background/Purpose: Temporal artery biopsy (TAB) is a reference test for establishing a diagnosis of giant cell arteritis (GCA). A subset of patients with a clinical…Abstract Number: 811 • 2017 ACR/ARHP Annual Meeting
The Presence of Giant Cells in the Temporal Artery Biopsy Is Associated with Reduced Risk of Future Large Vessel Involvement in Patients with Biopsy-Proven Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is a systemic disease with extensive vascular involvement. The mechanisms underlying the diversity of GCA phenotypes are incompletely understood. The…Abstract Number: 812 • 2017 ACR/ARHP Annual Meeting
Mortality Risk and Cause-Specific Mortality in Polymyalgia Rheumatica: A Population-Based Cohort Study
Background/Purpose: To determine mortality risk in polymyalgia rheumatic (PMR) and compare cause-specific mortality rates among patients with PMR to age- and sex-matched comparators from the…Abstract Number: 813 • 2017 ACR/ARHP Annual Meeting
Incidence of Herpes Zoster in Patients with Polymyalgia Rheumatica: A Population-Based Cohort Study
Background/Purpose: To determine the incidence, time trends and, severity of herpes zoster in a population-based incidence cohort of patients with polymyalgia rheumatic (PMR) compared to…Abstract Number: 814 • 2017 ACR/ARHP Annual Meeting
Clinical Presentation and Outcome of Orbital Mass in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides
Background/Purpose: Orbital mass is a rare ophthalmologic manifestation of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) that remains a therapeutic challenge. This study aimed to describe…Abstract Number: 815 • 2017 ACR/ARHP Annual Meeting
Incidence in Large Vessel GCA in Northern Italy during a 11-Year Period
Background/Purpose: there are few studies regarding the incidence of large vessel GCA (LV GCA). Purpose: to investigate the incidence in patients diagnosed with large vessel…Abstract Number: 816 • 2017 ACR/ARHP Annual Meeting
Comparison between Giacta Trial and a Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice with Tocilizumab
Background/Purpose: GiACTA study is a randomized, phase III controlled clinical trial of tocilizumab (TCZ) in giant cell arteritis (GCA) (1,2). Our aim was to compare…Abstract Number: 817 • 2017 ACR/ARHP Annual Meeting
Extension of Affected Vascular Territories in Secondary Aortitis Is Associated to Different Clinical Subtypes?
Background/Purpose: Aortitis is characterized by inflammation of the aortic wall. Aortitis may be associated with different conditions. Our aim was to assess if the different…Abstract Number: 818 • 2017 ACR/ARHP Annual Meeting
Correlation between the Routine Assessment of Patient Index Data (RAPID3) and Inflammatory Markers in Patients with PMR
Background/Purpose: The routine assessment of patient index data (RAPID3) was developed for monitoring and prognosis of patients with Rheumatoid Arthritis and has since been extended…Abstract Number: 819 • 2017 ACR/ARHP Annual Meeting
Risks of Non-Cardiovascular Corticosteroid Related Adverse Events and Cancer in Giant Cell Arteritis: A French Population-Based Cohort Study
Background/Purpose: Corticosteroid related adverse events are a main concern in patients suffering from giant cell arteritis. Conflicting results are reported on this topic, recurrent events…Abstract Number: 820 • 2017 ACR/ARHP Annual Meeting
Prognostic Value of Positron Emission Tomography in a Prospective, Longitudinal Cohort of Patients with Large Vessel Vasculitis
Background/Purpose: While several studies have examined the potential of 18F-flurodeoxyglucose (FDG) positron emission tomography (PET) to help establish a diagnosis of large vessel vasculitis (LVV),…
ACR Meeting Abstracts